Baohui Hu

机构：China Medical University · ORCID：0000-0001-5121-893X

发表论文 12 篇 · 总被引 478 次 · h-index 10

代表论文

• Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals (2025 · Journal of Hematology & Oncology · 被引 278)
• Advances in cancer treatment: a new therapeutic target, Annexin A2 (2021 · Journal of Cancer · 被引 45)
• A Immune-Related Signature Associated with TME Can Serve as a Potential Biomarker for Survival and Sorafenib Resistance in Liver Cancer (2021 · OncoTargets and Therapy · 被引 32)
• m6A RNA Methylation Regulators Impact Prognosis and Tumor Microenvironment in Renal Papillary Cell Carcinoma (2021 · Frontiers in Oncology · 被引 32)
• Development of an IFNγ response‐related signature for predicting the survival of cutaneous melanoma (2020 · Cancer Medicine · 被引 22)
• Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma (2020 · International Immunopharmacology · 被引 20)